Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P07437
UPID:
TBB5_HUMAN
Alternative names:
Tubulin beta-5 chain
Alternative UPACC:
P07437; P05218; Q8WUC1; Q9CY33
Background:
Tubulin beta chain, specifically the Tubulin beta-5 chain, plays a pivotal role in cell structure and function as the major constituent of microtubules. These cylindrical structures, composed of alpha- and beta-tubulin heterodimers, are essential for various cellular processes including cell division, intracellular transport, and the maintenance of cell shape.
Therapeutic significance:
The Tubulin beta chain's involvement in disorders such as Cortical dysplasia, complex, with other brain malformations 6, and Congenital symmetric circumferential skin creases, 1, underscores its potential as a target for therapeutic intervention. Understanding the role of Tubulin beta chain could open doors to potential therapeutic strategies.